Clinical Trial Update: Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating panobinostat (LBH589) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-09